The knockdown of NRF2, in fact, increases the susceptibility of HCC cells to antitumor action of ferroptosis inducers, like erastin and sorafenib, both in vivo and in vitro [87,88]. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.